ArticleNature2024
Spike deep mutational scanning helps predict success of SARS-CoV-2 clades.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed.
- Trial
- Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains.Emerging microbes & infections · 2026Article
- A machine learning method for calculating highly localized protein stabilities.Nature communications · 2026Article
- Potent type-specific de novo antibodies complement broadly reactive imprinted antibodies in immune responses to SARS-CoV-2 variants.Nature immunology · 2026Article
- Serum Escape Landscape of SARS-CoV-2 Omicron JN.1 and XEC RBD Under COVID-19 Vaccine Breakthrough Immunity in China.Microorganisms · 2026Article
- From sites to structure to serology: a roadmap for structure-aware molecular evolution of antigenically evolving viruses.Journal of virology · 2026Review
- Concepts of RNA virus evolution for the design of better antiviral countermeasures.Nature reviews. Microbiology · 2026Review
- Receptor-mimicking antibodies retain neutralization of recent SARS-CoV-2 variants.Biosafety and health · 2026Article
- Genetic diversity of pangolin coronaviruses reveals a key immuno-evasive substitution at spike residue 519.Journal of virology · 2026Article
- Scanning the horizon: deep mutational scanning approaches in virology.Journal of virology · 2026Review
- Fitness translocation: improving variant effect prediction with biologically-grounded data augmentation.Bioinformatics (Oxford, England) · 2026Article
- A deep mutational scanning-informed protein language model predicts SARS-CoV-2 evolution dynamics with spatiotemporal resolution.Nature microbiology · 2026Article
- Computationally hybridized pathogenic mammarenavirus receptor binding domains reveal cryptic variants that elicit cross-neutralizing immune responses.bioRxiv : the preprint server for biology · 2026Article
- Functional and structural characterization of the SARS-CoV-2 spike N481K mutation.Archives of virology · 2026Article
- PRIME: An evaluation framework for protein representation inference and generalization in viral mutation space.BMC genomics · 2026Article
- Epistasis and background dependence in the evolution of Omicron variants of the SARS-CoV-2 spike protein.Molecular biology and evolution · 2026Article
- Structural basis for sarbecovirus Rc-o319 spike adaptation to Rhinolophus cornutus Bat ACE2 and constraints on switching to human ACE2.PLoS pathogens · 2026Article
- TMPRSS2-mediated coronavirus spike activation and inhibition.Nature structural & molecular biology · 2026Article
- CountESS: a flexible, graphical pipeline tool for deep mutational scanning analysis.bioRxiv : the preprint server for biology · 2026Article
- Constrained evolutionary funnels shape viral immune escape.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
14 authors.
Bernadeta DadonaiteBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0003-0908-6982
Jack BrownDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Teagan E McMahonBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ariana G FarrellBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Marlin D FigginsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Daniel AsarnowDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Cameron StewartDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0002-2786-6256
Jimin LeeDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Jenni LogueUniversity of Washington, Department of Medicine, Division of Allergy and Infectious Diseases, Seattle, WA, USA.ORCID 0000-0002-7889-8960
Trevor BedfordVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Ben MurrellDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-0393-4445
Helen Y ChuUniversity of Washington, Department of Medicine, Division of Allergy and Infectious Diseases, Seattle, WA, USA.ORCID 0000-0001-8502-9600
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA, USA.ORCID 0000-0002-6019-8675
Jesse D BloomBasic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA. jbloom@fredhutch.org.ORCID 0000-0003-1267-3408
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00015 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI HENSLEY, SCOTT · 2021 to 2025
$50.7MCenters for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI MYLER, PETER · 2022 to 2025
$21.7MStructure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI Neil King · 2022 to 2026
$15.3MUnraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4MProspectively characterizing the functional and antigenic effects of mutations to viral entry proteinsR01AI141707 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2018 to 2022
$2.1MHigh-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0MFHCRC High-Performance Computing ClusterS10OD020069 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2015 to 2015
$600kNCI NIH HHS P30 CA015704NIAID NIH HHS 75N93021C00015NIAID NIH HHS 75N93022C00036NIAID NIH HHS DP1 AI158186NIAID NIH HHS P01 AI167966NIAID NIH HHS R01 AI141707NIH HHS S10 OD020069NIH HHS S10 OD028685
Abstract
SARS-CoV-2 variants acquire mutations in the spike protein that promote immune evasion
Indexed as
DNA Mutational AnalysisEvolution, MolecularGenetic FitnessImmune EvasionMutationSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralBinding SitesCOVID-19HEK293 CellsHumansNeutralization TestsProtein BindingACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.